azilect
teva b.v. - rasagilín - parkinsonova choroba - antiparkinsonické lieky - azilect je indikovaný na liečbu idiopatickej parkinsonovej choroby (pd), ako monotherapy (bez levodopa), alebo ako doplnok terapie (s levodopa) u pacientov s end-of-dávka výkyvy.
trifed expectorant
hikma farmaceutica (portugal) s.a., portugalsko - expektoranciá - 52 - expectorantia, mucolytica
robitussin expectorans na vykašliavanie 100 mg/5 ml sirup
haleon czech republic s.r.o., Česká republika - guajfenezín - 52 - expectorantia, mucolytica
mucosolvan long effect
opella healthcare slovakia s.r.o., slovensko - ambroxol - 52 - expectorantia, mucolytica
materiál dentálny výplňový ips empress direct, ips empress direct effect/color/opaque
ivoclar vivadent ag bendererstrasse 2 9494 schaan lichtenštajnsko -
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
ibalgin duo effect
opella healthcare slovakia s.r.o., slovensko - nesteroidové antiflogistiká na lokálne použitie - 29 - antirheumatica, antiphlogistica, antiuratica
celaskon long effect
zentiva, k.s., Česká republika - kyselina askorbová (vit.c) - 86 - vitamina, vitagena
mucosin tablety
sanofi-aventis slovakia s.r.o., slovensko - ambroxol - 52 - expectorantia, mucolytica
deltyba
otsuka novel products gmbh - delamanid - tuberkulóza, odolná voči viacerým liečivám - antimycobacterials - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 a 5. je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní antibakteriálne agentov.